Lymphoma (follicular non-Hodgkin's) - rituximab
Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37)
| Guidance type: Technology appraisal |
| Date issued: February 2008 |
We will consult on our review plans for this guidance in December 2010. |
| Reference: TA137 |
SummaryThis guidance replaces NICE technology appraisal guidance 37 issued in March 2002. The Institute reviews each piece of guidance it issues. The review and re-appraisal of the use of rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma has resulted in a change in the guidance. In people with relapsed stage III or IV follicular non-Hodgkin's lymphoma, rituximab is now an option in combination with chemotherapy to induce remission or alone as maintenance therapy during remission. Rituximab monotherapy is also an option for people with relapsed or refractory disease when all alternative treatment options have been exhausted. |
| Top |
DocumentsFor healthcare professionals
For patients, carers and the public
Background information |
Implementing this guidanceAny further information NICE has produced to help the NHS implement this guideline locally is linked to below: |
| Top |
